Destiny Pharma PLC unveils further positive results for c-difficile treatment as market research points to its commercial potential
NTCD-M3, which scientists are readying to section III clinical trials, was the topic to a
cdifficile
Summit Therapeutics PLC says c-difficile trial slowed by coronavirus pandemic disruption
US infectious ailments agency BARDA is encouraging to fund the demo with a grant value